Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giancarlo Comi, Gloria Dalla Costa & Lucia Moiola. (2021) Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. Expert Review of Neurotherapeutics 21:1, pages 21-34.
Read now
Read now
Yara Dadalti Fragoso, Tarso Adoni, Soniza Vieira Alves-Leon, Samira Luisa Apostolos-Pereira, Yuna Ribeiro de Araujo, Jefferson Becker, Joseph Bruno Bidin Brooks, Eber Castro Correa, Alfredo Damasceno, Carlos Augusto de Albuquerque Damasceno, Maria Lucia B. Ferreira, Paulo Diniz da Gama, Rodrigo Assad Diniz da Gama, Sidney Gomes, Marcus Vinicius Magno Goncalves, Anderson Kuntz Grzesiuk, Suzana Costa Nunes Machado, Andre Palma da Cunha Matta, Maria Fernanda Mendes, Taysa Alexandrino Goncalves Jube Ribeiro, Cristiane Franklin da Rocha, Heloisa Helena Ruocco, Henry Sato, Renata Faria Simm, Carlos Bernardo Tauil, Claudia Cristina Ferreira Vasconcelos & Vera Lucia Ferreira Vieira. (2016) Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis. Expert Review of Clinical Pharmacology 9:4, pages 541-546.
Read now
Read now
Alberto Gajofatto, Marco Turatti, Salvatore Monaco & Maria Donata Benedetti. (2015) Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug, Healthcare and Patient Safety 7, pages 157-167.
Read now
Read now
Articles from other publishers (12)
Dimos D. Mitsikostas, Anastasios Orologas, Efthimios Dardiotis, Nikolaos Fakas, Triantafyllos Doskas, Klimentini Karageorgiou, Maria Maltezou, Ioannis Iliopoulos, Michail Vikelis & Nikolaos Grigoriadis. (2023) A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod. Advances in Therapy 40:5, pages 2217-2233.
Crossref
Crossref
Silje Agnethe Stokke Kvistad, Joachim Burman, Anne Kristine Lehmann, Andreas Tolf, Christina Zjukovskaja, Guro Kristin Melve, Lars Bø & Øivind Torkildsen. (2022) Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. Journal of Neurology, Neurosurgery & Psychiatry 93:8, pages 844-848.
Crossref
Crossref
Tamás Biernacki, Dániel Sandi, Judit Füvesi, Zsanett Fricska-Nagy, Tamás Zsigmond Kincses, Péter Ács, Csilla Rózsa, Enikő Dobos, Botond Cseh, László Horváth, Zsuzsanna Nagy, Attila Csányi, Krisztina Kovács, Tünde Csépány, László Vécsei & Krisztina Bencsik. (2022) The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLOS ONE 17:4, pages e0267346.
Crossref
Crossref
Juan Ignacio Rojas, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano & Francisco Sánchez. (2020) Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders 39, pages 101931.
Crossref
Crossref
Erica Curti, Elena Tsantes, Eleonora Baldi, Luisa Maria Caniatti, Diana Ferraro, Patrizia Sola & Franco Granella. (2019) The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study. Multiple Sclerosis and Related Disorders 33, pages 146-152.
Crossref
Crossref
S Viswanathan. (2018) Efficacy and safety of Fingolimod therapy in multi-ethnic Malaysian patients with relapsing remitting multiple sclerosis: A longitudinal observational study. Journal of Clinical Neuroscience 54, pages 25-28.
Crossref
Crossref
Thomas Roux, Elisabeth Maillart, Jean-Sébastien Vidal, Sophie Tezenas du Montcel, Catherine Lubetzki & Caroline Papeix. (2017) Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center. Frontiers in Neurology 8.
Crossref
Crossref
Guillermo Izquierdo, Fátima Damas, Maria Dolores Páramo, Juan Luis Ruiz-Peña & Guillermo Navarro. (2017) The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLOS ONE 12:4, pages e0176174.
Crossref
Crossref
Tjalf Ziemssen, Jennie Medin, C. Anne-Marie Couto & Catherine R. Mitchell. (2017) Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmunity Reviews 16:4, pages 355-376.
Crossref
Crossref
Andrea Harrer, Georg Pilz, Katrin Oppermann, Marlene Sageder, Shahrzad Afazel, Elisabeth Haschke-Becher, Theo Rispens, Annick de Vries, Mark McCoy, Vlado Stevanovic, Wolfgang Hitzl, Eugen Trinka, Jörg Kraus, Johann Sellner & Peter Wipfler. (2017) From natalizumab to fingolimod in eight weeks — Immunological, clinical, and radiological data in quest of the optimal switch. Clinical Immunology 176, pages 87-93.
Crossref
Crossref
Veronika Tichá, Roman Kodým, Zuzana Počíková & Pavla Kadlecová. (2016) Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study. Clinical Drug Investigation 37:2, pages 175-186.
Crossref
Crossref
D. Baroncini, M. Zaffaroni, P. O. Annovazzi, S. Baldini, A. Bianchi, G. Minonzio, G. Comi & A. Ghezzi. (2016) A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study. Multiple Sclerosis and Demyelinating Disorders 1:1.
Crossref
Crossref